Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 13, 2007, Pages 3550-3557

  Kiselyov, Alexander S ^a   Milligan, Daniel ^b   Ouyang, Xiaohu ^b  

^a CHEMDIV INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

1 (2 (Pyridin 4 yl)ethyl) 1H azole 5 carboxamides; Angiogenesis; Dual kinase inhibitors; Receptor tyrosine kinase; Vascular endothelial growth factor receptor 2; VEGFR 1; VEGFR 2

Indexed keywords

1 [2 (PYRIDIN 4 YL)ETHYL] 1H AZOLE 5 CARBOXAMIDE; ADENOSINE TRIPHOSPHATE DERIVATIVE; AMIDE; CARBOXYLIC ACID DERIVATIVE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PHTHALAZINE DERIVATIVE; PYRROLE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ARTICLE; CELL ACTIVITY; CELL STRAIN CACO 2; COMPETITIVE INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTESTINE ABSORPTION; MOLECULE; PERMEABILITY;

ADENOSINE TRIPHOSPHATE; AMIDES; AZOLES; BINDING, COMPETITIVE; CACO-2 CELLS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; PHTHALAZINES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34250162117     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.042     Document Type: Article

References (33)

1. Risau W. Nature 386 (1997) 671
2. Klagsburn M., and Moses M.A. Chem. Biol. 6 (1999) R217
3. Hanahan D., and Folkman J. Cell 86 (1996) 353
4. Eskens F. Br. J. Cancer 90 (2004) 1
5. Eskens F., Olsson A.-K., Dimberg A., Kreuger J., and Claesson-Welsh L. Nat. Rev. Mol. Cell Biol. 7 (2006) 359
6. Zachary I. Biochem. Soc. Trans. 31 (2003) 1171
7. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Nature Rev. Drug Discov. 3 (2004) 391
8. Saaristo A., Karpanen T., and Alitalo K. Oncogene 19 (2000) 6122
9. Folkman J. Nat. Med. 1 (1995) 27
10. Fuh G., Li B., Crowley C., Cunningham B.C., and Wells J.A. J. Biol. Chem. 273 (1998) 11197
11. Barleon B., Totzke F., Herzog C., Blanke S., Kremmer E., Siemeister G., Marme D., and Martiny-Baron G. J. Biol. Chem. 272 (1997) 10382
12. Kiselyov A.S., Balakin K., and Tkachenko S.E. Expert. Opin. Invest. Drugs 16 (2007) 83
13. ™ (Bevacizumab, Genentech, San Francisco, CA) has recently been approved for the treatment of colorectal cancer, see. Culy C. Drugs Today 41 (2005) 23
14. ™ (Pegaptanib sodium, Eyetech Pharmaceuticals, New York, NY and Pfizer) has recently been approved to treat neovascular age-related macular degeneration; see. Fine S.L., Martin D.F., and Kirkpatrick P. Nat. Rev. Drug Disc. 4 (2005) 187
15. Ciardello F., Caputo R., Damiano V., Caputo R., Troiani T., Vitagliano D., Carlomagno F., Veneziani B.M., Fontanini G., Bianco A.R., and Tortora G. Clin. Cancer Res. 9 (2003) 1546
16. Drevs J., Konerding M.A., Wolloscheck T., Wedge S.R., Ryan A.J., Ogilvie D.J., and Esser N. Angiogenesis 7 (2004) 347
17. Hess-Stumpp H., Haberey M., and Thierauch K.H. Chembiochem 6 (2005) 550
18. Manley P.W., Furet P., Bold G., Bruggen J., Mestan J., Meyer T., Schnell C.R., and Wood J. J. Med. Chem. 45 (2002) 5687
19. Piatnitski E.L., Duncton M., Katoch-Rouse R., Sherman D., Kiselyov A.S., Milligan D., Balagtas C., Wong W., Kawakami J., and Doody J. Bioorg. Med. Chem. Lett. 15 (2005) 4696
20. Duncton M., Piatnitski E.L., Kiselyov A.S., Milligan D., Balagtas C., Smith II L., Katoch-Rouse R., Sherman D., and Doody J. Bioorg. Med. Chem. Lett. 16 (2006) 1579
21. Kiselyov A.S., Semenova M., Semenov V.V., and Piatnitski E.L. Chem. Biol.& Drug Design 68 (2006) 250
22. Kiselyov A.S., Semenov V.V., and Milligan D. Chem. Biol.& Drug Design 68 (2006) 308
23. Kiselyov A.S., Piatnitski L.E., Samet A.V., Kisly V.P., and Semenov V.V. Bioorg. Med. Chem. Lett. 17 (2007) 1369
24. Gill M.L., Frederickson M., Cleasby A., Woodhead S.J., Carr M.G., Woodhead A.J., Walker M.T., Congreve M.S., Devine L.A., O'Reilly D., Seavers L.C.A., Davis D.J., Curry J., Anthony R., Padova A., Murray C.W., Carr R.A.E., and Jhoti H. J. Med. Chem. 48 (2005) 414
25. Kaiser K., Spagnuolo C.J., Adams T.C., Audia V.H., Dupont A.C., Hatoum H., Lowe V.C., Prosser J.C., Sturm B.L., and Noronha L. J. Med. Chem. 35 (1992) 4415
26. Deredas D., and Frankowski A. Carbohydr. Res. 252 (1994) 275
27. 6; δ, ppm): 10.5, 13.2, 33.9, 58.5, 115.2, 122.7, 123.0, 128.9, 130.5, 133.4, 144.7, 145.5, 150.1, 162.4; ESI MS (M+1): 356, (M-1): 354; HRMS, exact mass calcd. ...
28. 2, and 2 mM DTT, 1 mg/ml BSA) containing 0.5 mmol pGAT-biotin and 3-4 ng KDR enzyme was added to each well. After 5-10-min preincubation, the kinase reaction was initiated by the addition of 10 μl of 10 μM ATP in the reaction buffer, after which the plate was incubated at room temperature for 45 min. The reaction was stopped by addition of 50 μl of KF buffer (50 mM Hepes, pH 7.5, 0.5 M KF, and 1 mg/ml BSA) containing 100 mM EDTA and 0.36 μg/ml PY20K (Eu-cryptate labeled anti-phosphotyrosine antibody, CIS bio international) was added and after an additional 2 h incubation at RT, the plate was analyzed in a RUBYstar HTRF Reader.
29. 50 represents the concentration of compound that caused 50% reduction in absorbance at 562 nm relative to untreated cells using sulfurhodamine B assay. Values were means of three independent determinations (SD < 10%).
30. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.C., Villafranca J.E., and Appelt K. Structure 7 (1999) 319
31. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The Protein Data Bank Nucl. Acids Res. 28 (2000) 235
32. Jain R.K. Science 307 (2005) 58
33. 4, absorbance was measured at 450 nm.